StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Imbruvica (ibrutinib) by Quarter

Imbruvica (ibrutinib) — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

AbbVie Imbruvica (ibrutinib): -29.4% in Q2 2026, down 19.9 pts from a year earlier. That is the lowest of the 35 quarters on record here.

Latest, Q2 2026
-29.4%
Period ended Jun 30, 2026
Change on a year earlier
-19.9 pts
-9.5% in Q2 2025
History
35 quarters
Since Q4 2017
Sources
35
Documents cited below

Where the Q2 2026 figure comes from

“|| Imbruvica b | 337 | 195 | 532 | (37.8) | (7.8) | (29.4) | (7.8) | (29.4)”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedImbruvica (ibrutinib) — Worldwide reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-29.4%-19.9 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 2026-24.7%-12.8 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 2025-20.8%-14.6 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 2025-14.8%-6.0 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 2025-9.5%-1.3 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 2025-11.9%-7.4 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 2024-6.2%+12.8 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 2024-8.8%+11.2 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024-8.2%+12.6 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 2024-4.5%+20.7 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 2023-19.0%+0.5 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 2023-20.0%-2.6 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 2023-20.8%-3.7 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 2023-25.2%-17.8 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-19.5%-16.8 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 2022-17.4%-17.7 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Cite this data

StockData. (2026). AbbVie Imbruvica (ibrutinib) (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/imbruvica-ww-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.